Fox Run Management L.L.C. Has $661,000 Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Fox Run Management L.L.C. cut its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 2.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,809 shares of the biopharmaceutical company’s stock after selling 76 shares during the quarter. Fox Run Management L.L.C.’s holdings in Alnylam Pharmaceuticals were worth $661,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the stock. Regeneron Pharmaceuticals Inc. bought a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth about $1,045,822,000. Geode Capital Management LLC raised its stake in Alnylam Pharmaceuticals by 3.2% during the 3rd quarter. Geode Capital Management LLC now owns 2,147,203 shares of the biopharmaceutical company’s stock worth $589,209,000 after buying an additional 66,928 shares during the period. American Century Companies Inc. boosted its holdings in Alnylam Pharmaceuticals by 0.7% in the fourth quarter. American Century Companies Inc. now owns 1,604,024 shares of the biopharmaceutical company’s stock worth $377,443,000 after acquiring an additional 11,291 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in Alnylam Pharmaceuticals by 5.5% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 513,962 shares of the biopharmaceutical company’s stock valued at $120,940,000 after acquiring an additional 26,614 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 3.0% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 286,703 shares of the biopharmaceutical company’s stock valued at $67,464,000 after acquiring an additional 8,462 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $290.70 on Tuesday. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. The firm has a market cap of $37.63 billion, a price-to-earnings ratio of -133.96 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39. The firm’s 50-day simple moving average is $257.81 and its two-hundred day simple moving average is $260.02.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). As a group, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In related news, CFO Jeffrey V. Poulton sold 967 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $246,749.39. Following the completion of the transaction, the chief financial officer now directly owns 32,786 shares in the company, valued at approximately $8,366,003.62. The trade was a 2.86 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Phillip A. Sharp sold 11,250 shares of the stock in a transaction on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total value of $3,093,750.00. The disclosure for this sale can be found here. Insiders have sold a total of 71,234 shares of company stock worth $19,958,097 over the last ninety days. 1.50% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Royal Bank of Canada increased their target price on Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the stock an “outperform” rating in a report on Friday. JPMorgan Chase & Co. raised shares of Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $280.00 to $328.00 in a research note on Monday. Bank of America lifted their price objective on shares of Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a “buy” rating in a report on Friday. HC Wainwright upped their target price on shares of Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the stock a “buy” rating in a report on Monday, February 24th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $320.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $312.30.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.